Literature DB >> 8632608

Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer.

H Miyamoto1, T Shuin, I Ikeda, M Hosaka, Y Kubota.   

Abstract

PURPOSE: Allelic losses within several tumor suppressor genes have been detected frequently in various types of human cancer. We investigated the roles and possible interactions of the tumor suppressor genes p53, Rb, DCC and APC in bladder cancer.
MATERIALS AND METHODS: Loss of heterozygosity (LOH) of these 4 genes was examined in 45 human bladder cancers by polymerase chain reaction and restriction fragment length polymorphism assay.
RESULTS: Of the evaluated cases, LOH was seen at P53 in 38%, at Rb in 22%, at DCC in 36% and at APC in 6% of tumors. Loss of heterozygosity at p53 and Rb was predominantly observed in high grade (grade 3) and/or invasive (T2 or greater) tumors, whereas LOH at DCC was present irrespective of tumor grade and stage. Allelic losses at either p53, Rb, DCC or APC were seen in 82% of high grade tumors, but in only 21% of low grade (grade 1 and 2) tumors (p<0.005). Similarly, 71% of invasive tumors had LOH at one or more loci compared with 20% of superficial (Ta and T1) tumors (p<0.005). Interestingly, p53-LOH and Rb-LOH were often observed simultaneously in the same tumor.
CONCLUSIONS: These results suggest that loss of the p53, Rb and/or DCC genes is involved in most of the late and some of the early steps of bladder carcinogenesis.

Entities:  

Mesh:

Year:  1996        PMID: 8632608

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

3.  DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer.

Authors:  W El-Rifai; D Kamel; M L Larramendy; S Shoman; Y Gad; S Baithun; M El-Awady; S Eissa; H Khaled; S Soloneski; M Sheaff; S Knuutila
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.

Authors:  Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

5.  β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.

Authors:  I Ahmad; J P Morton; L B Singh; S M Radulescu; R A Ridgway; S Patel; J Woodgett; D J Winton; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

Review 6.  Exploring molecular genetics of bladder cancer: lessons learned from mouse models.

Authors:  Imran Ahmad; Owen J Sansom; Hing Y Leung
Journal:  Dis Model Mech       Date:  2012-03-15       Impact factor: 5.758

7.  Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells.

Authors:  M Guy; M Moorghen; J A Bond; T J Collard; C Paraskeva; A C Williams
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

8.  Loss of heterozygosity in (LewisxF344)F1 rat urinary bladder tumors induced with N-butyl-N-(4-hydroxybutyl)nitrosamine followed by dimethylarsinic acid or sodium L-ascorbate.

Authors:  T Chen; Y Na; H Wanibuchi; S Yamamoto; C C Lee; S Fukushima
Journal:  Jpn J Cancer Res       Date:  1999-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.